Navigation Links
Nuevolution Announces Worldwide Technology Cross-Licensing Agreement With GSK
Date:7/28/2009

COPENHAGEN, Denmark, July 28 /PRNewswire/ -- Nuevolution today announced the execution of a worldwide technology cross-licensing agreement with GlaxoSmithKline.

The agreement relates to a number of patented technologies for rapid synthesis and DNA-tagging of hundreds of millions of chemically diverse drug-like small molecule compounds and the efficient screening of these, facilitating the identification of potent drug leads. These technologies were developed by Nuevolution and Praecis Pharmaceuticals, a wholly owned subsidiary of GlaxoSmithKline.

Under the terms of the cross-licensing agreement, GlaxoSmithKline will obtain a non-exclusive license under technology patents of Nuevolution, and Nuevolution will obtain a one time license fee and a non-exclusive license under technology patents of GlaxoSmithKline.

Further details of the agreement are not disclosed.

"By entering into this agreement, both companies are offered an optimal basis for continued development and application of the technologies" said Allen Oliff, SVP Molecular Discovery Research of GSK and Alex Gouliaev, CEO of Nuevolution A/S continued "our innovative technologies allow small molecule hit and lead discovery at an unprecedented scale. This agreement secures both companies the rights to operate these powerful technologies to their fullest extent".

About Nuevolution

Nuevolution is a leading lead discovery company founded in 2001 and based in Copenhagen, Denmark. The company has developed Chemetics(R), a unique, patent protected hybrid of proven wet chemistry and molecular biology which represents the ultimate fragment based lead discovery technology. Chemetics(R) enables rapid synthesis and DNA-tagging of hundreds of millions of chemically diverse drug-like small molecule compounds and the efficient screening of these, facilitating the identification of potent drug leads at unprecedented quantity, quality and speed compared to existing lead discovery technologies.

Nuevolution partners its technology with pharmaceutical and biotechnology companies, and is also developing an internal pipeline by applying Chemetics(R) to validated cancer and cardiovascular targets. Nuevolution has demonstrated the power of Chemetics(R) by identifying highly potent and drug like novel ligands with the potential to address major unmet medical needs across a range of therapeutic areas and target classes.

Nuevolution is a privately owned company and has raised EUR 37 million in financing from key Scandinavian investors, including SEB Venture, Sunstone Capital, SLS Invest and Novo A/S. For more information about Nuevolution A/S, please visit the company's website http://www.nuevolution.com

    For further information please contact:

    Nuevolution A/S
    Alex Haahr Gouliaev, CEO
    T: +45-70-20-09-87
    ahg@nuevolution.com



'/>"/>
SOURCE Nuevolution A/S
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Nuevolution Announces Progress in Its Collaboration With Merck & Co. Inc.
2. Nuevolution Announces Research and Development Collaboration with Merck & Co. Inc.
3. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
4. SEQUENOM Announces Launch of MassARRAY Compact 96 System
5. Human Genome Sciences Announces Proposed Public Offering of Common Stock
6. Webcast Alert: Neurocrine Biosciences Announces 2nd Quarter 2009 Earnings Results
7. Sechrist Industries, World Leader in Hyperbaric Chambers, Announces Edward Pulwer as President/CEO
8. Orexigen(R) Therapeutics Announces Full Exercise of Overallotment Option by Underwriters
9. PROLOR Biotech Announces $10 Million Preferred Stock Line From Members of The Frost Group
10. Spectrum Announces Fetal Bovine Serum Product Line
11. Cell Therapeutics, Inc. Announces Exercise of Overallotment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 04, 2016 , ... Proove Biosciences, Inc. , the commercial and ... McGill University . The partnership is designed to advance research in pain genetics ... patients in pain. With the new agreement, researchers at Proove Biosciences are able to ...
(Date:5/4/2016)... ... May 04, 2016 , ... Nutrafol®, a first-to-market ... treat hormonal and stress related hair loss. With patent-pending formulas for both female ... opinion leaders in the medical and salon channels nationwide. , Dermatologists, Plastic ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... ... announced the addition of Dr. Nancy Gillett to its Board of Directors. Dr. ... she served as Corporate Executive Vice President and Chief Scientific Officer. A board-certified ...
(Date:5/3/2016)... ... ... According to world renowned prostate cancer surgeon, Dr. David B. Samadi ... main treatment options: surgery or radiation. Based on a patient’s goals, disease state, and ... doctors to administer higher doses of radiation to prostate cancer patients with ...
Breaking Biology Technology:
(Date:3/9/2016)... , March 9, 2016 ... identified that more than 23,000 public service employees either ... been receiving their salary unlawfully.    --> ... government identified that more than 23,000 public service employees ... had been receiving their salary unlawfully.    --> ...
(Date:3/3/2016)... 3, 2016  2016FLEX, organized by FlexTech, a ... advancements in flexible, hybrid and printed electronics. More ... - have gathered for short courses, technical session, ... electronics. The Flex Conference celebrates its 15 th ... R&D organizations, and universities contributing to the adoption ...
(Date:3/1/2016)... , March 1, 2016 ... the addition of the  "Global Biometric ...  report to their offering. --> ... addition of the  "Global Biometric Access ... to their offering. --> ...
Breaking Biology News(10 mins):